CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma

This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.

Source: CancerNetwork - April 7, 2017 Category: Cancer & Oncology Authors: Frederick Locke, MD Tags: Conferences/AACR 2017 Videos Hematologic Malignancies Source Type: news